Transient Inhibition of P53 Enhances Prime Editing and Cytosine Base-editing Efficiencies in Human Pluripotent Stem Cells

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Oct 27

PMID 36302757

Authors

Mu Li

Aaron Zhong

Youjun Wu

Mega Sidharta

Michael Beaury

Xiaolan Zhao

Lorenz Studer

Ting Zhou

Affiliations

Soon will be listed here.

Abstract

Precise gene editing in human pluripotent stem cells (hPSCs) holds great promise for studying and potentially treating human diseases. Both prime editing and base editing avoid introducing double strand breaks, but low editing efficiencies make those techniques still an arduous process in hPSCs. Here we report that co-delivering of p53DD, a dominant negative fragment of p53, can greatly enhance prime editing and cytosine base editing efficiencies in generating precise mutations in hPSCs. We further apply PE3 in combination with p53DD to efficiently create multiple isogenic hPSC lines, including lines carrying GBA or LRRK2 mutations associated with Parkinson disease and a LMNA mutation linked to Hutchinson-Gilford progeria syndrome. We also correct GBA and LMNA mutations in the patient-specific iPSCs. Our data show that p53DD improves PE3 efficiency without compromising the genome-wide safety, making it feasible for safe and routine generation of isogenic hPSC lines for disease modeling.

Citing Articles

Robust and inducible genome editing via an all-in-one prime editor in human pluripotent stem cells.

Wu Y, Zhong A, Sidharta M, Kim T, Ramirez B, Persily B Nat Commun. 2024; 15(1):10824.

PMID: 39737975 PMC: 11685797. DOI: 10.1038/s41467-024-55104-1.

Prime editing: therapeutic advances and mechanistic insights.

Murray J, Harrison P, Scholefield J Gene Ther. 2024; .

PMID: 39609594 DOI: 10.1038/s41434-024-00499-1.

STRAIGHT-IN Dual: a platform for dual, single-copy integrations of DNA payloads and gene circuits into human induced pluripotent stem cells.

Blanch-Asensio A, Ploessl D, Wang N, Mummery C, Galloway K, Davis R bioRxiv. 2024; .

PMID: 39464154 PMC: 11507887. DOI: 10.1101/2024.10.17.616637.

Reporter Alleles in hiPSCs: Visual Cues on Development and Disease.

Cotta G, Teixeira Dos Santos R, Costa G, Lacerda S Int J Mol Sci. 2024; 25(20).

PMID: 39456792 PMC: 11507014. DOI: 10.3390/ijms252011009.

Advancing CRISPR base editing technology through innovative strategies and ideas.

Fan X, Lei Y, Wang L, Wu X, Li D Sci China Life Sci. 2024; 68(3):610-627.

PMID: 39231901 DOI: 10.1007/s11427-024-2699-5.

References

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

Zhong A, Li M, Zhou T . Protocol for the Generation of Human Pluripotent Reporter Cell Lines Using CRISPR/Cas9. STAR Protoc. 2020; 1(2). PMC: 7566848. DOI: 10.1016/j.xpro.2020.100052. View

Zafra M, Schatoff E, Katti A, Foronda M, Breinig M, Schweitzer A . Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol. 2018; 36(9):888-893. PMC: 6130889. DOI: 10.1038/nbt.4194. View

Engstrom J, Kmiec E . Manipulation of cell cycle progression can counteract the apparent loss of correction frequency following oligonucleotide-directed gene repair. BMC Mol Biol. 2007; 8:9. PMC: 1797188. DOI: 10.1186/1471-2199-8-9. View

Raczy C, Petrovski R, Saunders C, Chorny I, Kruglyak S, Margulies E . Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. Bioinformatics. 2013; 29(16):2041-3. DOI: 10.1093/bioinformatics/btt314. View

Porto E, Komor A, Slaymaker I, Yeo G . Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020; 19(12):839-859. PMC: 7721651. DOI: 10.1038/s41573-020-0084-6. View

Gaudelli N, Komor A, Rees H, Packer M, Badran A, Bryson D . Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017; 551(7681):464-471. PMC: 5726555. DOI: 10.1038/nature24644. View

Bartlett D, Davis M . Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006; 34(1):322-33. PMC: 1331994. DOI: 10.1093/nar/gkj439. View

Kim Y, Komor A, Levy J, Packer M, Zhao K, Liu D . Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol. 2017; 35(4):371-376. PMC: 5388574. DOI: 10.1038/nbt.3803. View

10.

Byrne S, Ortiz L, Mali P, Aach J, Church G . Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. Nucleic Acids Res. 2014; 43(3):e21. PMC: 4330342. DOI: 10.1093/nar/gku1246. View

11.

Zhou T, Benda C, Dunzinger S, Huang Y, Ho J, Yang J . Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012; 7(12):2080-9. DOI: 10.1038/nprot.2012.115. View

12.

Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H . Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019; 364(6437):289-292. PMC: 7301308. DOI: 10.1126/science.aav9973. View

13.

Hendriks W, Warren C, Cowan C . Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions. Cell Stem Cell. 2016; 18(1):53-65. PMC: 4709030. DOI: 10.1016/j.stem.2015.12.002. View

14.

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

15.

Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A . An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2012; 31(3):458-66. DOI: 10.1002/stem.1293. View

16.

Ihry R, Worringer K, Salick M, Frias E, Ho D, Theriault K . p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018; 24(7):939-946. DOI: 10.1038/s41591-018-0050-6. View

17.

Kim D, Moon S, Ko J, Kim Y, Kim D . Unbiased investigation of specificities of prime editing systems in human cells. Nucleic Acids Res. 2020; 48(18):10576-10589. PMC: 7544197. DOI: 10.1093/nar/gkaa764. View

18.

Eriksson M, Brown W, Gordon L, Glynn M, Singer J, Scott L . Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003; 423(6937):293-8. PMC: 10540076. DOI: 10.1038/nature01629. View

19.

Doench J, Fusi N, Sullender M, Hegde M, Vaimberg E, Donovan K . Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):184-191. PMC: 4744125. DOI: 10.1038/nbt.3437. View

20.

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin I . Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009; 324(5928):797-801. PMC: 2758053. DOI: 10.1126/science.1172482. View